AI for Diagnosis of Ejection Fraction

Bay Labs – Echocardiogram EF determination

San Francisco-based privately held company Bay Labs gained FDA approval in June 2018 for the fully automated and AI-based selection of the left ventricular ejection fraction (EF). Note that Healthcare Weekly has included Bay Labs is our list of the most promising healthcare startups to watch for in 2019.

With EF noted as the single most widely used metric of cardiac function, used as the basis for numerous clinical decisions, Bay Labs’ AI based EchoMD and AutoEF algorithms work to reduce the errors and minimise workflow that surrounds the industry. The algorithms eliminate the need to manually select views, choose the best clips, and manipulate them for quantification, which is often noted as a particularly time-consuming and highly variable process.

The algorithms automatically review all relevant information and digital clips from a patient’s echocardiography study and proceeds to rate accordingly with image quality as the focus criteria. What may be most impressive about Bay Labs’ artificial intelligence solution is the method that the system ‘learned’ clip selection in which over 4 million images were used to maximise algorithm success.

Ultimately, EchoMD and AutoEF will strive to maximise workflow efficiency while reducing the error in clinical decision making by helping physicians make correct choices.

Comments: